GlassScriptPhysician profile
Rudolf Khusid
NPI 1396792313
$14,279.40
in general payments reported to CMS, 2019-2025
38 companies · $2,828 in 2025
The $2,828 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $1,629 · 2021: $1,336 · 2022: $2,335 · 2023: $2,554 · 2024: $2,437 · 2025: $2,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,719 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,719.19 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,133.43 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,835.46 | 2019-2025 | Trelegy Ellipta, Nucala |
| Jazz Pharmaceuticals INC. | $1,629.55 | 2019-2025 | |
| Harmony Biosciences LLC | $920.77 | 2020-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $765.84 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $509.82 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $486.81 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $380.04 | 2019-2025 | Xolair |
| Avadel Cns Pharmaceuticals, LLC | $376.61 | 2023-2025 | Lumryz |
| Amgen INC. | $249.21 | 2021-2025 | Tezspire |
| Axsome Therapeutics, INC. | $233.19 | 2022-2025 | Sunosi |
| Mylan Specialty L.P. | $229.23 | 2019-2024 | Yupelri |
| Insmed, INC. | $217.86 | 2019-2025 | Arikayce |
| Verona Pharma, INC. | $196.65 | 2025 | Ohtuvayre |
| Philips North America LLC | $153.49 | 2019-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $120.31 | 2019-2021 | |
| Grifols USA, LLC | $91.65 | 2020-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $90.39 | 2022-2024 | Aralast |
| Vifor Pharma, INC. | $78.74 | 2024-2025 | Zemaira |
| Mallinckrodt Hospital Products INC. | $75.66 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $71.04 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $59.04 | 2019-2023 | |
| Pulmonx Corporation | $52.08 | 2022-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Resmed Corp | $44.46 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $41.30 | 2019-2022 | |
| Viatris Specialty LLC | $36.43 | 2025 | Yupelri |
| Electromed, INC. | $24.13 | 2025 | Smartvest |
| Shire North American Group INC | $22.30 | 2019 | |
| Baxter Healthcare | $19.25 | 2022 | |
| Inspire Medical Systems, INC. | $19.06 | 2025 | Inspire |
| Sunovion Pharmaceuticals INC. | $16.94 | 2020 | |
| Kaleo, INC. | $16.18 | 2019 | |
| Lilly USA, LLC | $15.34 | 2025 | Zepbound |
| Abbvie INC. | $15.05 | 2025 | |
| Circassia INC. | $14.21 | 2019 | |
| Hikma Pharmaceuticals USA | $13.81 | 2022 | |
| Eisai INC. | $13.06 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudolf Khusid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.